Suzhou, China

Daiwu Kang

USPTO Granted Patents = 10 

 

 

Average Co-Inventor Count = 3.3

ph-index = 3

Forward Citations = 23(Granted Patents)


Location History:

  • Kunshan, CN (2022 - 2024)
  • Suzhou, CN (2022 - 2024)

Company Filing History:


Years Active: 2022-2025

Loading Chart...
Loading Chart...
Loading Chart...
10 patents (USPTO):Explore Patents

Title: **The Innovative Contributions of Daiwu Kang**

Introduction

Daiwu Kang, a prominent inventor based in Suzhou, China, has made significant contributions to the field of nucleic acid research and pharmaceutical sciences. With a total of nine patents to his name, Kang is making strides in the development of innovative solutions for critical health issues.

Latest Patents

Kang's latest patents focus on innovative uses of small interfering RNA (siRNA) to inhibit the expression of specific genes. One notable patent details a siRNA designed to inhibit the expression of the apolipoprotein C3 (ApoC3) gene. This invention includes a pharmaceutical composition and a conjugate that contains the siRNA, featuring modified nucleotides that enhance its efficacy. The sense strand of this siRNA holds a nucleotide sequence that closely resembles a specified sequence with minimal variation.

Additionally, another significant patent pertains to a siRNA aimed at inhibiting the hepatitis B virus gene. This invention also emphasizes the use of modified nucleotides, with both the sense strand and antisense strand carefully constructed to meet the precise specifications required for effective gene inhibition.

Career Highlights

Daiwu Kang's career has been largely defined by his role at Suzhou Ribo Life Science Company, Ltd. Here, he has contributed his expertise in molecular biology and biochemistry to advance the company's research initiatives. His work focuses on putting cutting-edge scientific discoveries into practical applications that can improve patient outcomes in diverse medical areas.

Collaborations

Kang has collaborated closely with talented colleagues, including Hongyan Zhang and Shan Gao. Together, they have fostered an environment of innovation and shared knowledge, leading to the successful development of various pharmaceutical compositions and gene-targeting treatments.

Conclusion

Daiwu Kang's innovative work in the field of nucleic acids is paving the way for new therapeutic solutions. With a commitment to research and collaboration, he continues to make impactful strides in the science of gene expression and therapy, reflecting the significant role that dedicated inventors play in advancing healthcare technologies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…